Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
scallop-derived plasmalogens
- Development stage
- Preclinical
- Lead developer
- LABO Nutrition
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Oral
01
Overview
Scallop-derived plasmalogens are ethanolamine phospholipids (EPls) extracted from the Japanese scallop (Pecten yessoensis) using patented technology developed at Kyushu University. These compounds are intended to replenish plasmalogen levels in the brain, which are significantly reduced in patients with neurodegenerative diseases. The therapeutic mechanism includes the suppression of neuroinflammation, protection against oxidative stress and neuronal apoptosis, promotion of neurogenesis, and reduction of amyloid-β protein accumulation. Clinical studies have demonstrated that oral supplementation with 1 mg/day of these plasmalogens can improve cognitive function in individuals with mild Alzheimer's disease and mild cognitive impairment (MCI). Currently, the product is marketed as a dietary supplement under the brand name NeuroREGAIN rather than as a prescription pharmaceutical.
- Brand names
- NeuroREGAIN
- Other names
- scallop-derived ethanolamine plasmalogensscallop-derived EPlsPecten yessoensis-derived plasmalogensscallop plasmalogens
02
Targets
Aβ (Amyloid-beta peptides and aggregates)
Beyond the preview
Go deeper on scallop-derived plasmalogens.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on scallop-derived plasmalogens.